These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 27634416)

  • 1. Quantitative analysis of plasma cell-free DNA and its DNA integrity in patients with metastatic prostate cancer using ALU sequence.
    Fawzy A; Sweify KM; El-Fayoumy HM; Nofal N
    J Egypt Natl Canc Inst; 2016 Dec; 28(4):235-242. PubMed ID: 27634416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating cell-free DNA integrity as a diagnostic and prognostic marker for breast and prostate cancers.
    Arko-Boham B; Aryee NA; Blay RM; Owusu EDA; Tagoe EA; Doris Shackie ES; Debrah AB; Adu-Aryee NA
    Cancer Genet; 2019 Jun; 235-236():65-71. PubMed ID: 31105051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma cell-free DNA and its DNA integrity as biomarker to distinguish prostate cancer from benign prostatic hyperplasia in patients with increased serum prostate-specific antigen.
    Feng J; Gang F; Li X; Jin T; Houbao H; Yu C; Guorong L
    Int Urol Nephrol; 2013 Aug; 45(4):1023-8. PubMed ID: 23779229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma cell-free DNA level and its integrity as biomarkers to distinguish non-small cell lung cancer from tuberculosis.
    Leng S; Zheng J; Jin Y; Zhang H; Zhu Y; Wu J; Xu Y; Zhang P
    Clin Chim Acta; 2018 Feb; 477():160-165. PubMed ID: 29113814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating free DNA integrity and concentration as independent prognostic markers in metastatic breast cancer.
    Cheng J; Holland-Letz T; Wallwiener M; Surowy H; Cuk K; Schott S; Trumpp A; Pantel K; Sohn C; Schneeweiss A; Burwinkel B
    Breast Cancer Res Treat; 2018 May; 169(1):69-82. PubMed ID: 29340881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of cell-free circulating DNA in plasma in patients with prostate cancer.
    Delgado PO; Alves BC; Gehrke Fde S; Kuniyoshi RK; Wroclavski ML; Del Giglio A; Fonseca FL
    Tumour Biol; 2013 Apr; 34(2):983-6. PubMed ID: 23269609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic and prognostic role of cell-free DNA testing for colorectal cancer patients.
    Bedin C; Enzo MV; Del Bianco P; Pucciarelli S; Nitti D; Agostini M
    Int J Cancer; 2017 Apr; 140(8):1888-1898. PubMed ID: 27943272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum DNA integrity index as a potential molecular biomarker in endometrial cancer.
    Vizza E; Corrado G; De Angeli M; Carosi M; Mancini E; Baiocco E; Chiofalo B; Patrizi L; Zampa A; Piaggio G; Cicchillitti L
    J Exp Clin Cancer Res; 2018 Jan; 37(1):16. PubMed ID: 29382392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of circulating serum DNA integrity in colorectal cancer patients.
    Yörüker EE; Özgür E; Keskin M; Dalay N; Holdenrieder S; Gezer U
    Anticancer Res; 2015 Apr; 35(4):2435-40. PubMed ID: 25862911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Value of the concentration and integrity of serum cell-free DNA for the clinical diagnosis of esophageal carcinoma].
    Qiu YW; Shen XJ; Jin CJ; Cao XJ; Ju SQ
    Zhonghua Zhong Liu Za Zhi; 2018 Dec; 40(12):905-910. PubMed ID: 30605980
    [No Abstract]   [Full Text] [Related]  

  • 11. Circulating cell-free DNA variables as marker of ovarian cancer patients: A pilot study.
    Stamenkovic S; Cheng J; Surowy H; Burwinkel B; Gündert M
    Cancer Biomark; 2020; 28(2):159-167. PubMed ID: 32176629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Significance of Measuring Global Hydroxymethylation of White Blood Cell DNA in Prostate Cancer: Comparison to PSA in a Pilot Exploratory Study.
    Grelus A; Nica DV; Miklos I; Belengeanu V; Ioiart I; Popescu C
    Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29156615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats.
    Umetani N; Kim J; Hiramatsu S; Reber HA; Hines OJ; Bilchik AJ; Hoon DS
    Clin Chem; 2006 Jun; 52(6):1062-9. PubMed ID: 16723681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of cell-free plasma DNA as a diagnostic marker for prostate cancer.
    Allen D; Butt A; Cahill D; Wheeler M; Popert R; Swaminathan R
    Ann N Y Acad Sci; 2004 Jun; 1022():76-80. PubMed ID: 15251943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypermethylation of the CpG islands in the promoter region flanking GSTP1 gene is a potential plasma DNA biomarker for detecting prostate carcinoma.
    Chuang CK; Chu DC; Tzou RD; Liou SI; Chia JH; Sun CF
    Cancer Detect Prev; 2007; 31(1):59-63. PubMed ID: 17291695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microsatellite analysis of allelic imbalance in tumour and blood from patients with prostate cancer.
    Schwarzenbach H; Chun FK; Müller I; Seidel C; Urban K; Erbersdobler A; Huland H; Pantel K; Friedrich MG
    BJU Int; 2008 Jul; 102(2):253-8. PubMed ID: 18336598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating cell-free DNA: a promising marker of regional lymphonode metastasis in breast cancer patients.
    Agostini M; Enzo MV; Bedin C; Belardinelli V; Goldin E; Del Bianco P; Maschietto E; D'Angelo E; Izzi L; Saccani A; Zavagno G; Nitti D
    Cancer Biomark; 2012; 11(2-3):89-98. PubMed ID: 23011155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chromosomal instability in cell-free DNA is a serum biomarker for prostate cancer.
    Schütz E; Akbari MR; Beck J; Urnovitz H; Zhang WW; Bornemann-Kolatzki K; Mitchell WM; Nam RK; Narod SA
    Clin Chem; 2015 Jan; 61(1):239-48. PubMed ID: 25348670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic and prognostic value of serum miR-15a and miR-16-1 expression among egyptian patients with prostate cancer.
    Zidan HE; Abdul-Maksoud RS; Elsayed WSH; Desoky EAM
    IUBMB Life; 2018 May; 70(5):437-444. PubMed ID: 29522280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostatic volume and ratio of free-to-total prostate specific antigen in patients with prostatic cancer or benign prostatic hyperplasia.
    Haese A; Graefen M; Noldus J; Hammerer P; Huland E; Huland H
    J Urol; 1997 Dec; 158(6):2188-92. PubMed ID: 9366341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.